RxDoctor Payments Data

Astrid Serauto Canache, MD

Interventional Cardiology · Katy, TXNPI 1619351996

Payments from drug & device makers

$13,871in general payments, 2019–2025

Across 175 payments — averaging $79.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Biotronik Inc.$3K
  • Medtronic$3K
  • Edwards Lifesciences$2K
  • Abiomed$618
  • Boston Scientific$568
  • plus $2K from 19 others

What the payments were for

  • Grants$3,03022%
  • Travel & lodging$4,70934%
  • Food & beverage$6,11944%
  • Education$120%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,871 in reported general payments places this provider in the 55th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$37,944
Medicare patients
527
Services billed
878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$58,642
XareltoRivaroxaban12$18,873
Amiodarone Hcl37$1,287
Metoprolol Succinate72$921
Atorvastatin Calcium90$821
Rosuvastatin Calcium51$737
Losartan Potassium55$603
Amlodipine Besylate68$462
Valsartan11$362
ClopidogrelClopidogrel Bisulfate24$315
Carvedilol56$252
Hydralazine Hcl21$233
Lisinopril28$169
Hydrochlorothiazide30$155
Nifedipine ErNifedipine17$142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$193$58,64245 claims
Johnson & JohnsonXarelto$102$18,87312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Katy

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →